Medexus Pharmaceuticals Inc (MDP) AI Stock Analysis

• Market Cap: C$87.10M
• Dividend Yield: N/A
• Average Volume (3M): 46.68K
• Price to Earnings (P/E): 65.7
• Beta (1Y): 1.36
• Revenue Growth: 0.03%
• EPS Growth: -17.30%
• Country: CA
• Employees: 82
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.03
• Shares Outstanding: 32,258,354
• 10 Day Avg. Volume: 30,861
• 30 Day Avg. Volume: 46,683
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$7.00
• Price Target Upside: 148.23% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 58 Neutral
• Price Target: C$3.00 ▲(6.38% Upside)

Medexus Pharmaceuticals Inc's overall stock score is primarily influenced by its mixed financial performance and high valuation concerns. The cautious optimism from the earnings call provides some positive outlook, particularly with the launch of GRAFAPEX. However, technical indicators and valuation metrics suggest potential risks, leading to a moderate overall score.

Positive Factors

Product Launch Success

The successful launch of GRAFAPEX, with significant early adoption, indicates strong market acceptance and potential for sustained revenue growth.

Reimbursement Approval

The NTAP reimbursement approval for GRAFAPEX enhances its market competitiveness and could drive increased adoption and revenue.

Debt Management

Improved debt management reflects financial discipline, enhancing the company's balance sheet strength and financial flexibility.

Negative Factors

Revenue Decline

The decline in revenue suggests challenges in maintaining sales momentum, which could impact future earnings and growth potential.

Profitability Challenges

The decline in adjusted EBITDA indicates pressure on profitability, which may affect the company's ability to reinvest in growth initiatives.

Tariff Impact

The expected tariff on EU imports could increase costs and impact margins, posing a risk to profitability and competitive positioning.

Medexus Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Medexus Pharmaceuticals Inc. (MDP) is a specialty pharmaceutical company focused on the development and commercialization of innovative and high-quality healthcare solutions for patients in North America. The company operates in the pharmaceuticals sector, providing a diverse portfolio of products across various therapeutic areas including autoimmune diseases, oncology, and pediatrics. Medexus is dedicated to addressing unmet medical needs and improving patient outcomes through its strategic product offerings and partnerships.

How the Company Makes Money

Medexus Pharmaceuticals Inc. generates revenue primarily through the sale of its pharmaceutical products. The company's revenue streams are derived from direct sales to healthcare providers, hospitals, and pharmacies in North America. Medexus's business model also includes strategic partnerships and licensing agreements that expand its product portfolio and market reach. These partnerships often involve collaborations with other pharmaceutical companies to co-promote or distribute products, thereby enhancing revenue potential. Additionally, Medexus may receive milestone and royalty payments from licensing arrangements, contributing to its overall earnings.

Medexus Pharmaceuticals Inc Financial Statement Overview

Summary

Medexus Pharmaceuticals has demonstrated strong revenue growth and improved profitability, with better cost management reflected in improved gross and net profit margins. However, operational efficiency issues and high liabilities remain concerns.

Income Statement

Medexus Pharmaceuticals has shown strong revenue growth over the years, particularly from 2022 to 2024, with a slight dip in 2025. The Gross and Net Profit Margins have improved significantly, suggesting better cost management and increased profitability. However, fluctuations in EBIT margins highlight some operational efficiency issues.

Balance Sheet

The company has strengthened its equity position over the years, with a substantial increase in stockholders' equity from 2022 to 2025. The Debt-to-Equity ratio has decreased, indicating reduced leverage. However, high total liabilities still pose a risk to financial stability.

Cash Flow

Operating cash flow has improved significantly, turning positive after periods of negative cash flow. The Free Cash Flow Growth Rate is robust, supporting financial flexibility. However, fluctuations in investing and financing cash flows suggest ongoing capital adjustments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	105.66M	108.33M	113.05M	108.10M	76.70M	79.66M
Gross Profit	55.52M	56.58M	59.51M	60.04M	37.93M	42.01M
EBITDA	15.92M	16.81M	19.28M	16.14M	15.16M	-23.61M
Net Income	806.00K	2.25M	-214.00K	1.22M	-2.88M	-28.26M
Balance Sheet
Total Assets	153.79M	171.84M	155.73M	161.33M	139.22M	148.51M
Cash, Cash Equivalents and Short-Term Investments	9.33M	23.97M	5.25M	13.07M	10.02M	18.70M
Total Debt	21.89M	37.18M	49.90M	94.72M	54.86M	56.40M
Total Liabilities	100.83M	119.69M	125.41M	187.70M	151.82M	130.50M
Stockholders Equity	52.96M	52.14M	30.32M	22.45M	17.79M	18.02M
Cash Flow
Free Cash Flow	16.94M	21.31M	18.45M	-1.81M	-8.89M	-5.72M
Operating Cash Flow	19.76M	24.03M	18.71M	-1.44M	-1.18M	5.04M
Investing Cash Flow	-7.87M	-6.00M	-3.48M	-1.72M	-8.20M	-11.70M
Financing Cash Flow	-11.00M	796.00K	-23.05M	6.41M	663.00K	18.68M

Medexus Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.82
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Negative. The current price of 2.82 is above the 20-day moving average (MA) of 2.82, below the 50-day MA of 2.90, and below the 200-day MA of 2.91, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 48.02 is Neutral, neither overbought nor oversold. The STOCH value of 59.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MDP.

Medexus Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	―	C$128.53M	15.40	22.62%	1.77%	16.82%	19.25%
OGI	―	C$298.20M	74.00	1.86%	―	38.86%	―
MDP	―	C$87.10M	65.69	1.88%	―	0.03%	-17.30%
MPH	―	C$11.38M	―	-7.15%	―	10.84%	48.57%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AQS	―	C$663.17K	―	―	―	192.96%	42.59%

Medexus Pharmaceuticals Inc Corporate Events

Medexus Pharmaceuticals Announces Election of Directors and Auditor Appointment

Medexus Pharmaceuticals held its virtual annual meeting of shareholders, where all director nominees were elected, and PricewaterhouseCoopers LLP was appointed as the company’s auditors. The approval of these proposals reflects strong shareholder support, potentially reinforcing Medexus’s strategic direction and stability in the pharmaceutical industry.

The most recent analyst rating on (TSE:MDP) stock is a Hold with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals Earnings Call: Cautious Optimism Amid Challenges

The recent earnings call for Medexus Pharmaceuticals was characterized by cautious optimism. The company highlighted several strategic achievements, including the successful launch of GRAFAPEX and improved gross margins. However, these positives were tempered by challenges such as declining revenues and adjusted EBITDA, increased expenses, and concerns about tariffs affecting costs. The overall sentiment was one of cautious optimism, with a focus on future growth driven by GRAFAPEX.

Medexus Pharmaceuticals Reports Strong Q1 2026 Results Driven by GRAFAPEX Launch

Medexus Pharmaceuticals reported fiscal Q1 2026 results with a net revenue of $24.6 million and a net income of $0.5 million. The company highlighted the positive market response to its new product, GRAFAPEX, which generated $3.0 million in net revenue and is expected to be accretive to cash flows by fiscal Q3 2026. Despite a decline in revenues from other products like Rupall due to generic competition, Medexus remains confident in GRAFAPEX’s potential to solidify its leadership in the allo-HSCT field, with significant formulary inclusions and orders from transplant centers.

The most recent analyst rating on (TSE:MDP) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals Announces First Fiscal Quarter 2026 Conference Call

Medexus Pharmaceuticals has scheduled a conference call on August 13, 2025, to discuss its first fiscal quarter results for the period ending June 30, 2025. The company will also participate in upcoming industry conferences, reflecting its active engagement in commercialization activities and maintaining its market presence.

The most recent analyst rating on (TSE:MDP) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals’ GRAFAPEX™ Receives NTAP Approval for 2026

Medexus Pharmaceuticals announced that GRAFAPEX™ (treosulfan) for Injection has received approval for New Technology Add-On Payment (NTAP) from the US Centers for Medicare & Medicaid Services for the fiscal year 2026. This approval marks a significant reimbursement milestone, allowing eligible procedures involving GRAFAPEX™ to receive additional reimbursement, thereby enhancing its accessibility to Medicare beneficiaries. Since its US commercial launch, GRAFAPEX™ has seen positive uptake, with several commercial payers and healthcare institutions including it in their formularies, indicating promising commercial potential.

The most recent analyst rating on (TSE:MDP) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.